Renovia Inc. is a company that discovered and delivered the first-line digital diagnostic and therapeutic devices. These devices help in the diagnosis and treatment of pelvic floor disorders in women. Renovia received a funding of $ 42.3 million that would be divided into two. $10 million would go to the business debt, and the remaining $ 32.3 Million goes to the Series B equity. The funds would help in supporting future commercial launches, corporate development, product development process, and the company’s clinical tests. Perceptive Advisors and Ascension Ventures led the series B process assisted by OSF Ventures, Cormorant Asset Management, and Longwood Fund. Others were Inova Strategic Investments, Cormorant Asset Management, and Western Technology Investment. Renova’s advisor in the process was BayCross Capital Group. Learn more: https://www.linkedin.com/in/marcbeer
The Chairman and the Chief Executive Officer who is also one of the Renovia Inc. founders Marc Beer thanked the group for supporting the noble idea. He noted that the supporters were leading healthcare companies that share the Renova Inc.’s vision of offering better diagnostic procedures as well as treating and improving the lives of the millions of pelvic floor disorder victims. He added that the company was thankful to have the three integrated healthcare networks and financial businesspersons because they go together with Renovia’s commercial and clinical vision. Beer also noted that the proprietary and innovative sensor technologies with the modern digital platform would provide the best services to the customers. Additionally, the customers would get valuable data informing them on the availability of contemporary treatment options, help them understand and have more knowledge on the pelvic floor disorders.
Marc Beer started Renovia Inc. in August 2016 in collaboration with the Ramon Iglesias and Yolanda Lorié. They succeeded in financing the company with the help of various healthcare venture fund in the series A process. Beer formerly worked for Viacell and sat in the Board Directors of NASDAQ: ERYP, Erytech Pharma. At Genzyme, Marc Beer worked as the Vice President of Global Marketing. Before joining Genzyme, Marc Beer worked in the sales department of NYSE: ABT, Abbott Chemicals. He served in Emerging Companies Section Governing Board of BIO, Biotechnology Industry Organization among other positions, Marc Beer is a graduate Miami University of Ohio where he pursued his Bachelors of Science degree.